MyWay – Patient Support
69
Quality Score
Solid
MyWay – Patient Support
Medium confidence
✍️ bumetric analysis
“
MyWay – Patient Support is an iOS app from Sanofi Winthrop Industrie in the Education category, currently rated 4.8★ across 1,647 ratings. Initial signal reads as largely positive sentiment, users highlighting consistency and feature depth.
Quality Score is 69: Solid (established niche player). For a Education app, that means established niche player. The full BU Investment Matrix below scores 8 dimensions including monetisation, growth, and operational risk.
Track changes month-over-month in the Performance section below: live snapshot history and revenue forecast included.
💰 Monthly revenue · now vs forecast
● Right now
$597
per month
→
12-mo forecast
$522 – $1883
per month
→
24-mo forecast
$484 – $4357
per month
INDIE tierFREE
💡 Grow this revenue
Free AI audit of this app’s store listing
- Title & subtitle keyword fit
- Description hook & conversion structure
- Screenshots, ratings, reviews strategy
Typical impact: +2-5× organic installs
📊 Performance Tracking LIVE
Loading…
Rating
—
Reviews
—
Forecast Revenue / mo
—
Snapshots tracked
0
since first record
ONE-TIME · BUILD
💰 Estimated build cost
$80K
↳ What it cost to build · not monthly revenue
Likely range $60K – $110K
$25K · MVP floor
$100K · indie scale
$500K+ · studio build
📈
Pays back in ~10 months at current MRR
Synthetic estimate. Inputs: category complexity, file size, screen count, monetization layer, platform reach, age × team-size proxy. Calibrated against 2024-2026 indie-agency rate surveys. Full math + source list on /methodology.
Where the money goes
| 🧱 MVP baseline (design + 1-store ship) | +$28K |
| 📱 5 unique screens × $4.5K | +$22K |
| 📦 Asset bundle (91 MB) | +$16K |
| ⚙ Education complexity ×1.20 | +$13K |
Total estimate
$80K
ONE-TIME · EXIT VALUE
💵 Estimated acquisition value
$150K
↳ What it would sell for · not monthly revenue
Marketplace range $100K – $200K · 18× MRR multiple
💸
~1.9× build cost (break-even+)
Synthetic estimate. Multiple band derived from ad-supported + age, rating quality, category demand, and user-base maturity. Calibrated against 2024-2026 indie-app-marketplace closed-deal medians. Full math + comparable deal list on /methodology.
How the multiple was built
| 📺 Ad-supported base | 15× MRR |
| ⭐ ★ rating ≥ 4.7 (premium) | +15% |
| 🏷 Education category multiple | +6% |
Final multiple
18× MRR
👥 Estimated audience size
135K
Lifetime downloads (US-equivalent)
Monthly active
24K
Daily active
7.2K
Synthetic estimate from ratings × category benchmarks. Calibrated against 2024-2026 mobile-attribution retention + DAU/MAU reports. Numbers are US-storefront-equivalent — true global audience can be 5-10× larger for international apps. Full math + source list on /methodology.
How we sized it
| 📲 Education engagement | ~85 installs / rating |
| 🔁 Education D30 retention | 18% |
| 📍 DAU / MAU stickiness | 0.30 |
DAU / MAU
30% sticky
🔬
How we forecast this revenue
LOW CONFIDENCEBaseline
$597/mo · ML-estimated from 234 triggers
Growth rate
+6.0% MoM · INDIE tier baseline (compound monthly)
Direction
Headwinds: low defensibility moat
6 months
$509 – $1.2K
12 months
$522 – $1.9K
24 months
$484 – $4.4K
Compound growth at +6.0% MoM (tier baseline for INDIE). Range widens with horizon — typical noise band ±40% at 6mo.. Ranges widen with horizon — distant futures carry more uncertainty.
📊
BU Investment Matrix
Pre-traction · 35/100INDIE TIERFREE (NO MONETIZATION)limited signalGrowth Velocity
5.0
Founder Strength
4.9
Product Quality
7.1
Revenue Strength
2.8
Monetization Maturity
0.5
Defensibility
2.6
Market Position
0.3
Operational Safety
4.6
- 💰 Revenue: Marginal — $239 - $1494/mo · INDIE tier · medium confidence, trajectory unclear.
- ⭐ Quality: 4.75★ across 1,647 reviews — solid.
- 📍 Market: Not yet charting in any of the 9 monitored markets.
- 📈 Growth: Insufficient signal to assess trajectory.
- ⚠️ Risk: Elevated — bug mentions above category norm, rating drift -2.43 ★ (recent 50 vs lifetime).
🎯 For competitors: Vulnerable. Quality drift + slow updates create a clear opening for a fresh competitor with active dev cadence.
💵 For acquirers: Estimated asking range 12-22× monthly = $7K-$13K. Portfolio play ($8K/mo combined) commands premium. Discount applied for operational risk..
Composite of 8 dimensions computed deterministically from public signals — no LLM, every score traces back to a measurable input. Default weights shown; "compete" / "acquire" / "invest" lenses re-weight without re-fetching.
Range:
💰 Forecast Revenue / mo
MODELRevenue forecast computed from BU's 234 trigger model on each snapshot. Calibrated against ground-truth from 58 verified-revenue apps.
🔬Forecast Breakdown — Why This Estimate?Top 5 of 5 triggers
Our ML model uses 200+ signals from public data. These are the most influential for this app:
| Excellent rating (4.8★)METRIC | +$2,200 | |
| Low install base (1,647 ratings)METRIC | +$1,500 | |
| highly recommendREVIEW | +$1,400 | |
| Ad-supported / freemiumMETRIC | +$600 | |
| Growing app (2y old)METRIC | +$200 |
METRIC = structural app data · REVIEW = mined from user reviews · ✓ VERIFIED = Stripe-verified anchor (TrustMRR)
📈 Reviews Growth
LIVECumulative review count from first BU snapshot. Each point = a tracked update.
⭐ Rating Trend
LIVEAverage rating evolution. Updates with each new review batch.
🆕 What's New · v3.4.0
This version includes functional updates.
Profile & Insights
Everything we know — and don't — about this app and its company.
Identification
- App name
- MyWay – Patient Support
- Developer
- Sanofi Winthrop Industrie
- Bundle ID
- com.sanofi.us.dupiapp.prod
- App Store URL
- Open in App Store
- Category
- Education
- Content rating
- 17+
- Languages
- AR, EN, DE, JA
Company
- Website
- Not found
- Tagline
- Today
- Description
- Find apps and games for iPhone, iPad, Mac, and more on the App Store.
- Founded
- Not found
- HQ / Address
- Not found
- Employees
- Not found
- Logo
- Available
Revenue
- Verified revenue / mo
- Not found
- AI revenue estimate / mo
- Not found
- AI annual estimate
- Not found
- ML model estimate / mo
- $8.1K/mo
- Top-grossing rank
- Outside top 100 in US Education
- All-time revenue
- Not found
- Pricing
- Not found
Founder
Founder data not yet collected for this app.
Funding
Funding data not yet collected for this app.
Press & Links
Press & Links data not yet collected for this app.
Contacts & Socials
Contacts & Socials data not yet collected for this app.
📈Ratings growth1,647 ratings+728% lifetimeShow 3-year history estimate ▾
Tracked (29 weeks) Pre-tracking estimate (25 weeks) · model-based, ±5% noise · anchored to release date and current value
🌍Geographic ReachNot ranked
This app is currently outside the top 100 grossing in all 9 countries we monitor (US, UK, DE, FR, JP, CA, AU, BR, IN). Niche or new apps often launch this way — popularity rankings appear once daily revenue clears the regional threshold.
Profile is built from iTunes Lookup + developer site scrape + ML revenue model. Empty fields show "Not found" — additional sources (Crunchbase, X, IndieHackers, Acquire.com) coming.
📝 About this app
Sanofi US is distributing this app on behalf of Sanofi and Regeneron Pharmaceuticals, Inc.
See full Prescribing Information and Patient Information for DUPIXENT® (dupilumab)
https://www.regeneron.com/downloads/dupixent_fpi.pdf
https://www.regeneron.com/downloads/dupixent_ppi.pdf
Personalized support for your treatment journey.
The MyWay app is a patient support tool designed to help you access DUPIXENT® (dupilumab) as quickly as possible, once you have a prescription, and to help you through your treatment journey.… View full description on the official store →
See full Prescribing Information and Patient Information for DUPIXENT® (dupilumab)
https://www.regeneron.com/downloads/dupixent_fpi.pdf
https://www.regeneron.com/downloads/dupixent_ppi.pdf
Personalized support for your treatment journey.
The MyWay app is a patient support tool designed to help you access DUPIXENT® (dupilumab) as quickly as possible, once you have a prescription, and to help you through your treatment journey.… View full description on the official store →
App Specs
🔐 Own this app? Claim & verify MRR →💾 91 MB🔞 17+📱 iOS 16.0+🔖 v3.4.0🔄 updated 0d ago🌐 AR, EN, DE, JA📂 Education💰 Paid
📅
What Worked™ · Development Pipeline
10 EVENTS TRACKEDDetected changes in this app over its tracked lifetime — each event links cause (what changed) to effect (what moved). Sorted newest first.See full history →Version history →
2026-05
⭐
Rating ↑ 2.46 → 4.75 (improved 2.29★)
2026-05
📈
Crossed 50 ratings — social-proof flywheel kicking in
2026-03
⭐
Rating ↓ 4.80 → 2.46 (dropped 2.34★)
2026-03
⭐
Rating ↑ 2.41 → 4.80 (improved 2.39★)
2026-03
📈
Crossed 50 ratings — social-proof flywheel kicking in
2024-10
⭐
Rating ↑ 1.89 → 2.20 (improved 0.31★)
2024-10
📈
Crossed 10 ratings — social-proof flywheel kicking in
2024-10
⭐
Rating ↑ 1.57 → 2.00 (improved 0.43★)
2024-09
⭐
Rating ↑ 1.25 → 1.80 (improved 0.55★)
2024-06
🚀
First tracked snapshot — initial data captured
🗣
Voice of Customer
Based on 31 reviews across 1 markets● 39% positive · ● 16% neutral · ● 45% negative · Rating drift: -2.43★ (declining — recent 50: 2.32★ vs lifetime: 4.75★)
VADER compound sentiment per quarter (−1 = fully negative, +1 = fully positive). Each point ≥ 5 reviews.
Top praise themes
take shot ×4 dupixent ×7 now ×5 thank ×4 calendar ×4 program ×4 dose ×3 helpful ×3
Top complaint themes
copay card ×5 journal entries ×3 invite code ×3 doesn work ×3 entry ×5 open ×5 one ×4 able ×4
Risk signals
Bug mentions: 10%
🔔
Track this app’s revenue
FREEGet an email when revenue moves by your threshold. No spam, unsubscribe in one click.
📝 Description
95
BU Score · Transcendent
Full revenue analysis
Read the article-style breakdown for MyWay – Patient Support: category rank, percentile, growth signal, comparable apps, and how the forecast is calibrated against verified-MRR anchors in this niche.
About this analysis
Why medium confidence: 1,647 ratings · no founder-verified revenue (model estimate only).
❓ Frequently Asked Questions
4 answers · auto-generated from this app's public dataHow much does MyWay – Patient Support make per month?▴
Based on our ML-calibrated revenue forecast, MyWay – Patient Support earns approximately $8.1K/mo. This is a US-storefront-equivalent estimate; global revenue can be several times larger for internationally-distributed apps. See the methodology page for the full formula and confidence bands.
What apps are like MyWay – Patient Support?▴
Browse the full Education category catalog to find similar apps with revenue, build cost, audience and tech stack data. Each /p/{slug} page also shows a Compare side-by-side widget with three peer apps from the same niche.
Who makes MyWay – Patient Support?▴
MyWay – Patient Support is published by Sanofi Winthrop Industrie on the Apple App Store. See the full publisher portfolio (other apps by the same developer) via the More by developer block on the product page above.
What is MyWay – Patient Support's BU Score?▴
MyWay – Patient Support has a BU Score of 69/100 (Solid). The score combines App Store rating, ratings count, monetization model and revenue signals calibrated against founder-verified MRR anchors. See the BU Score formula.